



22 OCTOBER, 2022
(SATURDAY)



08:30 - 16:00 HRS
UAE TIME



HYBRID
(IN-PERSON & VIRTUAL)



HALL B

Session 1

Chairperson:	TBA
08:30 - 08:45	IO Therapy in the Curative Setting Jordi Remon Masip, Spain
08:45 - 09:00	Adjuvant Therapy in Molecular Driver Mutation Positive Lung Cancer: ADAURA and Beyond Roy Herbst, USA
09:00 - 09:15	Stage III NSCLC - Advances in non-surgical Treatment Strategies Suresh Senan, Netherlands
09:15 - 09:25	Q & A
09:25 - 09:45	Satellite Symposium - TBA

Session 2

Chairperson:	TBA
09:45 - 10:00	Liquid Biopsy for Monitoring Natasha Leigh, Canada
10:00 - 10:15	Molecular landscape of NSCLC Amit Dutt, India
10:15 - 10:30	First Line Therapy for Non-driver mutated NSCLC Alfredo Addeo, Switzerland
10:30 - 10:45	Coffee Break
10:45 - 11:00	First Line Therapy for EGFR and ALK driven Tumors Ben Solomon, Australia
11:00 - 11:15	Q & A
11:15 - 11:35	Satellite Symposium - TBA

Session 3

Chairperson:	TBA
11:35 - 11:50	Beyond EGFR and ALK: Managing Driver Mutation Positive Lung Cancer Vivek Subbiah, USA
11:50 - 12:05	Brain mets and Leptomeningeal Disease Vijay Patil, India
12:05 - 12:20	2nd Line Therapy in Non-driver mutation Positive NSCLC Ullas Batra, India
12:20 - 12:35	2nd Line and beyond Therapy in Driver Mutation Positive NSCLC Zosia Piotrowska, USA
12:35 - 12:50	Management of Toxicities of Immunotherapy of NSCLC Jarushka Naidoo, USA
12:50 - 13:00	Q & A
13:00 - 13:15	Satellite Symposium - TBA
13:15 - 14:15	Lunch Break

Session 4

Chairperson:	TBA
14:15 - 14:30	Satellite Symposium - TBA
14:30 - 14:45	Optimal Symptom Management in a Patient with Lung Cancer Ishwaria Subbiah, USA
14:45 - 15:00	Geriatric Lung Cancer Vanita Noronha, India
15:00 - 15:15	Small Cell Lung Cancer TBA
15:15 - 15:30	Oligometastatic Disease Christine Lovly, USA
15:30 - 15:45	Bringing Equity to Lung Cancer Care Narjust Florez (Duma), USA
15:45 - 16:00	Q & A
16:00	Closing Remarks Kumar Prabhash, India